Eribulin plus Pyrotinib in Trastuzumab-Resistant, HER2-Positive Advanced Breast Cancer: A Single-Arm, Multicenter Phase II Trial (EPIC Trial)
Drug Design, Development and Therapy · 2025
DOI: 10.2147/dddt.s547569 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Drug Design, Development and Therapy, 2025. Verfasst von Ruoyang Li und 5 weiteren Autor:innen. Beteiligte Einrichtung: Breast Center, Fourth Hospital of Hebei Medical University, Shijiazhuang, People's Republic of China. Hauptthemen laut MEDLINE: Acrylamides, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Drug Resistance, Neoplasm. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Breast Center, Fourth Hospital of Hebei Medical University, Shijiazhuang, People's Republic of China.
- Department of Breast Surgery, Xingtai People's Hospital, Xingtai, People's Republic of China.
- Department of Breast Surgery, TangShan People's Hospital, Tangshan, People's Republic of China.
- Department of Oncology, Hebei Petrochina Central Hospital, Langfang, People's Republic of China.
ORCID-Profile: Meiqi Wang, Zhenchuan Song
Zitieren
APA
Li, R., Wang, M., Kong, X., Ma, J., Qi, X., & Song, Z. (2025). Eribulin plus Pyrotinib in Trastuzumab-Resistant, HER2-Positive Advanced Breast Cancer: A Single-Arm, Multicenter Phase II Trial (EPIC Trial). Drug Design, Development and Therapy. https://doi.org/10.2147/dddt.s547569
Vancouver
Li R, Wang M, Kong X, Ma J, Qi X, Song Z. Eribulin plus Pyrotinib in Trastuzumab-Resistant, HER2-Positive Advanced Breast Cancer: A Single-Arm, Multicenter Phase II Trial (EPIC Trial). Drug Design, Development and Therapy. 2025. doi:10.2147/dddt.s547569
BibTeX
@article{Li2025,
author = {Li, Ruoyang and Wang, Meiqi and Kong, Xiangshun and Ma, Jie and Qi, Xiuheng and Song, Zhenchuan},
title = {Eribulin plus Pyrotinib in Trastuzumab-Resistant, HER2-Positive Advanced Breast Cancer: A Single-Arm, Multicenter Phase II Trial (EPIC Trial)},
journal = {Drug Design, Development and Therapy},
year = {2025},
doi = {10.2147/dddt.s547569}
}
EUVIMED